Breaking Business News | Breaking business news AM | Breaking Business News PM

Here’s why Nestlé is buying a peanut-allergy company for $2.6B

31 Aug 2020

Nestlé is shelling out an estimated $2.6 billion to buy a biopharmaceutical company best known for its peanut-allergy treatment.

Nestlé is shelling out an estimated $2.6 billion to buy a biopharmaceutical company best known for its peanut-allergy treatment.


Read the full article here.
This content was originally published by Fast Company. Original publishers retain all rights. It appears here for a limited time before automated archiving. By Fast Company

Covid-19 – Johns Hopkins University

Download brochure

Introduction brochure

What we do, case studies and profiles of some of our amazing team.

Download